Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
Date:2/11/2010

opportunities and initiate the approval process in selected developed markets. -- Continue to pursue external strategic partnerships that leverage our balance sheet and strong nephrology and oncology franchises.

Conference Call

3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on February 12, 2010 to discuss its 2009 fourth quarter and annual financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

    Conference ID: 52340276
    Local dial-in:
     China - landline 800-819-0121
     China - mobile   400-620-8038
    International toll-free dial-in:
     Hong Kong        800930346
     United Kingdom   080-8234-6646
     United States    1-866-519-4004
    International toll dial-in: +65-6735-7955

A telephone replay will be available two hours after the call until February 20, 2010 at:

    Replay - Conference ID: 52340276
    International dial-in:  +61-2-8235-5000
    United States dial-in:  1-866-214-5335

Webcast

A live webcast of conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... , , , The proven activated dendrimer for transfection , ... Features and benefits , , ... Suitable for a broad range of cell lines , Transfection in ... Quantity vs. Transfection Efficiency ") , High transient and stable transfection ...
... , , , For transfection of a wide variety of cells, , ... Features and benefits , , ... transfection-complex removal needed for most cell lines , Transfection in the ... lines , High transfection efficiencies and minimal cytotoxicity, ...
... , , , , ... and Rosemarie Grantyn , Developmental Physiology, Johannes Mller ... , , Efficient ... importance for extending our knowledge of the molecular basis of neuronal ...
Cached Biology Technology:SuperFect Transfection Reagent 2SuperFect Transfection Reagent 3Effectene Transfection Reagent 2Effectene Transfection Reagent 3Effectene Transfection Reagent 4Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 2Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 3Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 4
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... biologists at the University of Pennsylvania say that species ... rate than in the past. In the study, ... researchers developed a novel computational approach to infer the ... present-day species. Using nine patterns of diversification as ...
... State University researchers have received a $1.5 million ... better account of their ecological footprint., Seven researchers ... Natural Resources, Biosystems Engineering, and USDA Agricultural Research ... nitrogentwo elements central to farming and out of ...
... more than $4.5 million, from agencies of the National ... treatment strategies for muscular dystrophy. The grants were ... and Skin Diseases (NIAMS), National Institute of Neurological Disorders ... of Child Health and Human Development (NICHD) for year ...
Cached Biology News:Penn biologists say species accumulate on Earth at slower rates than in the past 2WSU researchers taking sustainability of organic farming to new level 2NIH awards Muscular Dystrophy Cooperative Research Center grants 2
... shortages in your laboratory or fellow researchers want ... problems and delays. • ... Bring us your idea and let us build ... under ISO 9001 quality assurance in design, development, ...
...
... virus is a type I eukaryotic topoisomerase ... turns (also called right- and left-handed supercoils) ... the reaction is a covalently closed, circular ... turns. DNA Topoisomerase I does not absolutely ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: